Johnson & Johnson management check

JNJ · Health Care · Pharmaceuticals · CEO J. Duato

Filings as of

70
Management score, ranked 181st of 487 · 20th of 60 in Health Care4 good · 3 to watch · 0 flaggedStrongest: CEO cost · Weakest: owner returns · Best and worst run in Health Care →

The seven checks

  • Watch

    Have owners done well?

    Trailed its chosen peersOwners$152Peers$189

    What $100 became since fiscal 2022

    2533rd
    Detail

    $100 invested at the start of fiscal 2022 grew to $152, against $189 for the peer group the company picked itself.

  • Good

    Does pay follow performance?

    Pay rose and fell with returns20222025

    Pay actually paid $100 value, each on its own scale

    9788th
    Detail

    Over 4 years, the CEO's pay actually paid (equity valued at the share price) had a correlation of 0.93 with shareholder return. 1 means pay moved in step; below 0, the opposite way.

  • Good

    What does the CEO cost owners?

    0.1% of net income

    $32.8m pay · $26.8bn net income, FY2025

    0.1%1%3%10%
    100100th
    Detail

    $32.8m of reported pay in fiscal 2025, against $26.8bn of net income.

  • Watch

    Do they own the stock?

    CEO stake ≈ 3.2 years of pay

    399,258 shares ≈ $104.2m

    0.1y1y5y20y100y

    6 mo: ▲ $0 bought · ▼ $73.9m sold

    4044th
    Detail

    The CEO holds 399,258 shares, directly or through trusts (unvested awards not counted): about 3.2 years of pay. 6 insiders sold $73.9m in the last six months and none bought.

  • Good

    Are owners being diluted?

    Share count shrinking2021 · 2.7bn2025 · 2.4bn

    Diluted shares −2.6% a year; flagged above +2%

    0%10%20%

    Stock pay 1.4% of revenue

    8274th
    Detail

    Diluted shares changed -2.6% a year over the last three fiscal years. Stock-based pay was 1.4% of revenue in the latest year.

  • Watch

    Is leadership stable?

    2 CEOs in the pay table

    8 filings under 8-K 5.02 in 3 years

    0101420+

    CEOs: A. Gorsky, J. Duato

    4521st
    Detail

    CEOs in the pay table: A. Gorsky, J. Duato. 8 filings under 8-K item 5.02 (officers or directors leaving or joining, or new pay arrangements) in the last 3 years.

  • Good

    Are the books clean?

    No red flags on file

    Since 2021

    • 0Restated
    • 0Auditor changes
    • 0Late filings
    • 010-K amended
    100100th
    Detail

    No restatements, auditor changes or late filings since 2021.

  • Reading the scores

    Each check scored 0–100 from its own figure. The tick is the Health Care median; the ordinal is the share of ranked S&P 500 companies it matches or beats.

    Hover a chart for its figures. Detail has the full reading.

Pay versus performance

From the proxy statement filed March 11, 2026.

CEO pay as reportedActually paid ⓘWhat $100 becamePeer group the company chose
$0$34.1m$68.3m$1002022202320242025$152$189

Pay tied most to Annual relative total shareholder return

Other key measures•Operational sales•Three-year cumulative adjusted operational EPS•Adjusted operational EPS growth•Three-year TSR compound annual growth rate versus the competitor composite peer group•Free cash flow•Share price•Share price appreciation

Show the figures
Fiscal yearCEOCEO payActually paidOther executives (avg)$100 becamePeersNet income
2025J. Duato$32.8m$68.3m$12.5m$152$189$26.8bn
2024J. Duato$24.3m$17.0m$11.2m$103$148$14.1bn
2023J. Duato$28.4m$13.8m$12.5m$108$137$35.2bn
2022A. Gorsky$26.7m$39.4m$12.5m$111$126$20.9bn

Insiders and the CEO's stakeSelling

CEO and Chairman of the Board
Joaquin Duato
Shares held
399,258
At that filing's price
≈ $104.2m
Latest Form 4
Aug 13, 2026

6 insiders sold $73.9m in the last six months and none bought.

Open-market trades by officers and directors since May 21, 2026.

  • SoldJoaquin DuatoCEO and Chairman of the Board$44.7mAug 13, 2026
  • SoldTimothy SchmidEVP, WW Chair, MedTech$9.2mSep 2, 2026
  • SoldElizabeth ForminardEVP, Chief Legal Officer$7.8mNov 12, 2026
  • SoldVanessa BroadhurstEVP, Global Corp Affairs$5.8mJul 20, 2026

Leadership and governance on file

20222023202420252026Leadership 17Votes 5
All 17 filings

Latest shareholder vote results: Apr 28, 2026, including the say-on-pay vote.

Where the money went

2021–2025: $22.9bn returned to owners in buybacks and dividends, 20% of net income, and $6.0bn of pay in stock.

Net incomeBuybacksDividendsStock-based payDiluted shares
$0$17.6bn$35.2bn20212022202320242025Shares2.67bn2.66bn2.56bn2.43bn2.43bn
Show the figures
Fiscal year20212022202320242025
Revenue$78.7bn$80.0bn$85.2bn$88.8bn$94.2bn
Net income$20.9bn$17.9bn$35.2bn$14.1bn$26.8bn
Stock-based pay$1.1bn$1.1bn$1.2bn$1.2bn$1.4bn
Buybacks$3.5bn$6.0bn$5.1bn$2.4bn$6.0bn
Dividends—————
Diluted shares2674m2664m2560m2429m2429m

Educational only, not investment advice. Figures are as filed with the SEC: pay from the proxy's pay-versus-performance table, capital allocation from 10-K XBRL data, insider trades from Form 4s over the last six months, events from the last 5 years of filings. The peer group is the one the company chose. See the method.